Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Panelists discuss recent data updates on transplant-ineligible and deferred newly diagnosed multiple myeloma (NDMM), including findings from the CEPHEUS and IMROZ studies, and explore the clinical significance of minimal residual disease negativity as a prognostic and actionable factor in treatment decision-making for NDMM.
Video content above is prompted by the following:
- Please comment on recent data updates for transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM):
- CEPHEUS study, SubQ Dara-VRd vs VRd in transplant-ineligible NDMM
- IMROZ study, Isa-VRd vs VRd in TIE/deferred NDMM
- What is the clinical significance of minimal residual disease (MRD) negativity as a clinical outcome? How do you interpret and integrate MRD negativity into your clinical decision-making? Beyond its prognostic value, what actionable insights does MRD provide in guiding treatment strategies and patient management?
- Please highlight key insights from MRD analyses in NDMM presented at ASH 2024.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
